Merck presents positive results from phase 1/2 study evaluating V116
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Bringing next-gen cannabinoid therapeutics to cancer patients
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
Both manufacturing facilities are based out of Benguluru, India
Wedgewood Pharmacy operates compounding pharmacies that offers sterile and non-sterile compounded medications for animal patients in 50 states.
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
The innovative software module is designed to meet growing scientific demand from researchers and drug developers
The nadAROSE and nadia3D kits address the needs of researchers exploring both agarose encapsulation and collagen-based hydrogel projects for the 3D cell culture space.
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Subscribe To Our Newsletter & Stay Updated